Companies · Other Health Care

Rimidi, Inc.

ATLANTA · Other Health Care

Diligence memoA one-page analyst read on Rimidi, Inc. — recommendation, valuation, rhythm, risks.
$18.2M
Total raised · real
11
Rounds
0.6×
Latest step-up
Top 18%
Sector rank · raised
Series A
Latest stage · inferred · Fri Aug 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Rimidi, Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.09× the median modeled value of Series A Other Health Care companies in 2025–2027 (83 peers) — value vs value, same stage and era.
Active
  • Last raise 11 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Rimidi, Inc. is one of 5376 Other Health Care companies tracked from ATLANTA. By capital raised it ranks in the upper tier (ahead of 83% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2025-08-15
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MPre-Seed · 2012-08-01 Raised $100K (real) Modeled valuation $3.1M (est)Pre-Seed2012Seed · 2014-10-10 Raised $1.3M (real) Modeled valuation $33M (est)Seed2014Seed · 2015-04-22 Raised $500K (real) Modeled valuation $12M (est)Seed2015Seed · 2015-12-18 Raised $700K (real) Modeled valuation $17M (est)Seed2015Pre-Seed · 2015-12-18 Raised $300K (real) Modeled valuation $9.2M (est)Pre-Seed2015Series A · 2018-07-03 Raised $6.6M (real) Modeled valuation $134M (est)Series A2018Series A · 2021-06-29 Raised $306K (real) Modeled valuation $4.3M (est)Series A2021Series A · 2022-10-02 Raised $375K (real) Modeled valuation $3.4M (est)Series A2022Series A · 2022-12-28 Raised $5.0M (real) Modeled valuation $41M (est)Series A2022Series A · 2024-01-09 Raised $2.0M (real) Modeled valuation $11M (est)Series A2024Series A · 2025-05-09 Raised $800K (real) Modeled valuation $2.8M (est)Series A2025Series A · 2025-08-15 Raised $450K (real) Modeled valuation $1.4M (est)Series A2025Cumulative $18M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$100K · 2012
Seed$1.3M · 2014
Seed extension$500K · 2015
Seed extension$700K · 2015
Bridge · Seed-stage$300K · 2015smaller follow-on
Series A$6.6M · 2018
Series A extension$306K · 2021
Series A extension$375K · 2022
Series A extension$5.0M · 2022
Series A extension$2.0M · 2024
Series A extension$800K · 2025
Series A extension$450K · 2025

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$1.4M
Base estimate est.
$577K
Conservative case
$2.4M
Upside case
$2.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $3.1M · 2012-08-012012Seed · modeled $32.9M · 2014-10-10Seed · modeled $12.4M · 2015-04-22Seed · modeled $17.3M · 2015-12-18Pre-Seed · modeled $9.2M · 2015-12-18Series A · modeled $134.0M · 2018-07-03Series A · modeled $4.3M · 2021-06-29Series A · modeled $3.4M · 2022-10-02Series A · modeled $41.3M · 2022-12-28Series A · modeled $11.4M · 2024-01-09Series A · modeled $2.8M · 2025-05-09Series A · modeled $1.4M · 2025-08-152025
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
52%
Survival probability
28% low · 71% high
1.43×/yr
Annual markup
1.80×/yr upside case
0.9 yr
Elapsed time used
0.9 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
14 mo
Avg between rounds
$1.4M/yr
Capital velocity
13.9 yr
On record since
2012
First round
12
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 7.5× above median
This company$18.2M
Sector median$2.4M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.1× of median
This company$450K
Sector median$5.6M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$1.4M
Sector median$22.1M

Raised more than 83% of sector peers (real $). Modeled value above 7% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #76 of 83.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0M$10.0M$100.0MCapital raised (log)HelloJoy, Inc. · Series A Raised $26.3M · modeled $55.0M (est)Maui Imaging, Inc. · Series A Raised $29.9M · modeled $51.0M (est)Celltrio, Inc. · Series A Raised $15.0M · modeled $50.8M (est)Medmo, Inc. · Series A Raised $31.7M · modeled $44.7M (est)Vertical Orthopaedics, Inc. · Series A Raised $16.7M · modeled $44.0M (est)AbriCare, Inc. · Series A Raised $15.0M · modeled $39.1M (est)WP Stillwater, LLC · Series A Raised $14.3M · modeled $38.1M (est)Sylke, Inc. · Series A Raised $15.9M · modeled $37.6M (est)Iridex Corp · Series A Raised $10.0M · modeled $37.2M (est)2GHealth Inc. · Series A Raised $17.5M · modeled $35.6M (est)Okc Alf 4, Llc · Series A Raised $8.9M · modeled $34.5M (est)HC Jones, Inc. · Series A Raised $14.1M · modeled $33.4M (est)Rimidi, Inc. (this company) Raised $18.2M · modeled $1.4M (est)Rimidi, Inc.
CompanyStageRaised · realValue · estvs peer med.
HelloJoy, Inc.Series A$26.3M$55.0M3.37×
Maui Imaging, Inc.Series A$29.9M$51.0M3.12×
Celltrio, Inc.Series A$15.0M$50.8M3.11×
Medmo, Inc.Series A$31.7M$44.7M2.74×
Vertical Orthopaedics, Inc.Series A$16.7M$44.0M2.69×
AbriCare, Inc.Series A$15.0M$39.1M2.39×
WP Stillwater, LLCSeries A$14.3M$38.1M2.33×
Sylke, Inc.Series A$15.9M$37.6M2.30×
Iridex CorpSeries A$10.0M$37.2M2.28×
2GHealth Inc.Series A$17.5M$35.6M2.18×
Okc Alf 4, LlcSeries A$8.9M$34.5M2.11×
HC Jones, Inc.Series A$14.1M$33.4M2.04×
Rimidi, Inc. this companySeries A$18.2M$1.4M0.09×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$100K2012-08-01$556K$3.1M85%
Seed$1.3M2014-10-10$6.6M$32.9M85%
Seed$500K2015-04-22$2.5M$12.4M85%
Seed$700K2015-12-18$3.5M$17.3M90%
Pre-Seed$300K2015-12-18$1.7M$9.2M85%
Series A$6.6M2018-07-03$30.2M$134.0M90%
Series A$306K2021-06-29$1.4M$4.3M90%
Series A$375K2022-10-02$1.7M$3.4M90%
Series A$5.0M2022-12-28$22.7M$41.3M90%
Series A$2.0M2024-01-09$9.1M$11.4M90%
Series A$800K2025-05-09$3.6M$2.8M90%
Series A$450K2025-08-15$2.0M$1.4M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$100K2012-08-01
    • First recorded raise — entered as Pre-Seed.
    • 2 investors on this round.
  2. Seed$1.3M2014-10-10
    • Raised again after 26 mo — slower than the ~14 mo sector norm.
    • Round 13.3× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 06).
    • 14 investors on this round.
  3. Seed$500K2015-04-22
    • Came back fast: 6 mo vs the ~14 mo sector norm.
    • Round 2.7× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  4. Seed$700K2015-12-18
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
    • 6 investors on this round.
  5. Pre-Seed$300K2015-12-18
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.3× smaller than the prior — bridge or down round.
    • 4 investors on this round.
  6. Series A$6.6M2018-07-03
    • Raised again after 30 mo — slower than the ~14 mo sector norm.
    • Round 22.1× larger than the prior — scaling up.
    • 14 investors on this round.
  7. Series A$306K2021-06-29
    • Raised again after 36 mo — slower than the ~14 mo sector norm.
    • Round 21.7× smaller than the prior — bridge or down round.
    • 8 investors on this round.
  8. Series A$375K2022-10-02
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 6 investors on this round.
  9. Series A$5.0M2022-12-28
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 13.3× larger than the prior — scaling up.
    • 1 investor on this round.
  10. Series A$2.0M2024-01-09
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  11. Series A$800K2025-05-09
    • Raised 16 mo later, in step with the ~14 mo sector norm.
    • Round 2.5× smaller than the prior — bridge or down round.
    • 6 investors on this round.
  12. Series A$450K2025-08-15
    • Came back fast: 3 mo vs the ~14 mo sector norm.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 1 investor on this round.
Intelligence
2026 ~Q4
Modeled next raise · ~14mo cadence
$450K
Modeled next size est.range $450K$720K
0.6×
Last step-up
$1.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert Turner5 other2018-07
Bob Bozeman2 other2018-07
R. William Ide, III1 other2018-07
A. Michael Marie Albisser2012-08
Azam Marie Khan2021-06
Bob Marie Bozeman2014-10
Chris Marie McIlvoy2014-10
Christopher Marie McIlvoy2021-06
Christopher McIlvoy2018-07
Dirk Benson2025-05
Jennifer Ide2018-07
Jennifer Marie Ide2012-08
Joshua Claman2018-07
Kevin Bunker2024-01
Kirk Marie Barnes2022-12
Lucienne Ide2018-07
Lucienne Marie Ide2012-08
Mark Braunstein2024-01
Mark Marie Braunstein2021-06
Mark Marie Mlotek2022-12
Robert Marie DeHaven2012-08
Robert Marie Turner2021-06
R. William, III Ide2024-01
R. William, III Marie Ide2012-08
Registry & provenance

Rimidi, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1556272
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Trendlines Group Ltd.Other Health CareSeries A$18.5M$1.2Msame sector · same stage
OurPharma Holdings LLCOther Health CareSeries A$15.9M$824Ksame sector · same stage
South Campus Surgery Center LlcOther Health CareSeries A$15.3M$1.8Msame sector · same stage
RF Surgical Systems, IncOther Health CareSeries A$14.6M$2.4Msame sector · same stage
Wellist, Inc.Other Health CareSeries A$12.8M$1.3Msame sector · same stage
Tegria RCM Group - US, Inc.Other Health CareSeries A$11.8M$2.0Msame sector · same stage
Kelsey-Seybold Medical Group, PLLCHospitals and PhysiciansSeries A$14.2M$267.0Mnetwork1 shared operator · same stage
Theravida, Inc.Other Health CareSeries A$9.1M$1.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Cartiva, Inc.Other Health CareSeries A$141.3M86%
RIMSYS Inc.Other Health CareSeries B$37.5M86%
Azzly, Inc.Other Health CareSeed$7.3M85%
Digestiva, Inc.Other Health CareSeries B$120.4M85%
CoreMedica Laboratories Inc.Other Health CareSeed$61.1M84%
Hubly Inc.Other Health CareSeries A$24.4M84%
Toetal Solutions, Inc.Other Health CareSeed$3.5M84%
Amplifica, Inc.Other Health CarePre-Seed$15.4M84%
Frequently asked
How much funding has Rimidi, Inc. raised?
Rimidi, Inc. has raised approximately $18.2M in disclosed capital across 11 recorded financing rounds, aggregated from public filings.
What is Rimidi, Inc.'s estimated valuation?
Provath's modeled valuation for Rimidi, Inc. is approximately $1.4M (modeled range $577K–$2.4M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Rimidi, Inc. at?
Rimidi, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Aug 15.
What does Rimidi, Inc. do and where is it based?
Rimidi, Inc. operates in the Other Health Care sector, based in ATLANTA.
Explore related

See where Rimidi, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Rimidi, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.